RxDoctor Payments Data

Emily Dechow

Nurse Practitioner · Galesburg, ILNPI 1770147738

Payments from drug & device makers

$1,480in general payments, 2019–2025

Across 37 payments — averaging $40.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$321
  • Dexcom, Inc.$222
  • Insulet Corporation$199
  • Novo Nordisk$129
  • Boehringer Ingelheim$123
  • Corcept Therapeutics$116
  • plus $372 from 5 others

What the payments were for

  • Food & beverage$1,480100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,480 in reported general payments places this provider in the 85th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$70,722
Medicare patients
191
Services billed
1,207

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide394$672,996
TrulicityDulaglutide154$247,801
MounjaroTirzepatide183$245,688
JardianceEmpagliflozin95$106,224
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog124$86,242
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog59$75,823
Tresiba Flextouch U-100Insulin Degludec73$67,381
Tresiba Flextouch U-200Insulin Degludec42$61,244
RybelsusSemaglutide30$55,311
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/742$50,610
FarxigaDapagliflozin Propanediol52$45,213
JanuviaSitagliptin Phosphate49$42,827
Fiasp FlextouchInsulin Aspart (Niacinamide)48$41,724
Novolog FlexpenInsulin Aspart105$41,058
Lyumjev Kwikpen U-100Insulin Lispro-Aabc19$31,584

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$129$740,322449 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$28$510,471395 claims
Boehringer IngelheimJardiance, Tradjenta$123$116,767112 claims
Sanofi-aventis U.S. LLCLantus$95$8,90335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Galesburg

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →